Share This Page
Drug Price Trends for TAYSOFY
✉ Email this page to a colleague

Average Pharmacy Cost for TAYSOFY
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
TAYSOFY 1 MG-20 MCG CAPSULE | 65162-0558-16 | 0.79458 | EACH | 2025-01-22 |
TAYSOFY 1 MG-20 MCG CAPSULE | 65162-0558-58 | 0.79458 | EACH | 2025-01-22 |
TAYSOFY 1 MG-20 MCG CAPSULE | 65162-0558-16 | 0.73663 | EACH | 2024-12-18 |
TAYSOFY 1 MG-20 MCG CAPSULE | 65162-0558-58 | 0.73663 | EACH | 2024-12-18 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Taysofy
Introduction
Taysofy, launched by Amneal Pharmaceuticals, is an AB-rated generic equivalent for the oral contraceptive brand Taytulla®. This analysis will delve into the market dynamics, competitive landscape, and price projections for Taysofy.
Market Context
The pharmaceutical industry, particularly the generic drug market, is highly competitive and influenced by various factors such as regulatory approvals, market exclusivity, and pricing strategies.
Generic Drug Market
Generic drugs, like Taysofy, enter the market after the patent and market exclusivity periods of the brand-name drugs expire. This allows for lower-cost alternatives, increasing accessibility for patients. The launch of Taysofy follows the approval of its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA)[5].
Competitive Landscape
The oral contraceptive market is crowded with both brand-name and generic products. Taysofy competes directly with Taytulla® and other generic equivalents.
U.S. Annual Sales
In the 12 months ended June 2021, U.S. annual sales for Taytulla® and its generic equivalents were approximately $124.4 million. This indicates a significant market size for oral contraceptives, providing a substantial revenue potential for Taysofy[5].
Pricing Strategies
Pricing for generic drugs is generally lower than for brand-name drugs due to the absence of research and development costs and the competitive nature of the generic market.
Price Projections
Given the competitive landscape, the price of Taysofy is expected to be lower than that of Taytulla®. Here are some key points to consider:
- Generic Pricing: Generic drugs typically offer significant cost savings compared to their brand-name counterparts. For example, generic versions of drugs can be 70-80% cheaper than the brand-name versions[3].
- Market Dynamics: The overall drug price inflation rate is projected to be 0.00% for the period from January 1, 2025, to December 31, 2025, according to the Vizient Pharmacy Market Outlook. This suggests a stable pricing environment for pharmaceuticals, including generics like Taysofy[4].
Regulatory Environment
The regulatory environment plays a crucial role in the pricing and availability of generic drugs.
Market Exclusivity
Brand-name drug manufacturers enjoy a 12-to-16-year window of market exclusivity, which protects them from generic competition. Once this period ends, generic manufacturers like Amneal can enter the market with their own versions, leading to increased competition and lower prices[3].
Financial Projections
While specific financial projections for Taysofy are not available, we can infer from industry trends and the performance of similar generic drugs.
Revenue Potential
Given the $124.4 million in annual sales for Taytulla® and its generic equivalents, Taysofy has the potential to capture a significant share of this market. The revenue will depend on factors such as market penetration, pricing strategy, and competition from other generic versions.
Key Takeaways
- Market Size: The oral contraceptive market is substantial, with annual sales of over $124 million for Taytulla® and its generics.
- Pricing: Taysofy is expected to be priced lower than Taytulla®, aligning with typical generic drug pricing strategies.
- Regulatory Environment: The end of market exclusivity for brand-name drugs allows generic manufacturers to enter the market, increasing competition and reducing prices.
- Financial Projections: Taysofy has significant revenue potential, though exact figures depend on market dynamics and competitive strategies.
FAQs
-
What is Taysofy? Taysofy is an AB-rated generic equivalent for the oral contraceptive brand Taytulla®, launched by Amneal Pharmaceuticals.
-
How does Taysofy compete in the market? Taysofy competes with Taytulla® and other generic equivalents in the oral contraceptive market, offering a lower-cost alternative.
-
What are the price projections for Taysofy? Given the generic nature of Taysofy, it is expected to be priced lower than Taytulla®, with prices influenced by the overall stable pricing environment in the pharmaceutical sector.
-
What is the revenue potential for Taysofy? The revenue potential for Taysofy is significant, given the substantial market size for oral contraceptives, with annual sales exceeding $124 million for Taytulla® and its generics.
-
How does the regulatory environment impact Taysofy? The regulatory environment, particularly the end of market exclusivity for brand-name drugs, allows generic manufacturers like Amneal to enter the market, increasing competition and reducing prices.
Sources
- Amneal Pharmaceuticals Launches Taysofy™ – Generic for Taytulla® - RXinsider[5]
- Market Exclusivity and U.S. Prescription Drugs - Commonwealth Fund[3]
- Pharmacy Market Outlook Summer 2024 - Vizient Inc.[4]
More… ↓